From Nasdaq: 2025-04-01 13:23:00

GE HealthCare Technologies Inc. completed the acquisition of the remaining 50% stake in Nihon Medi-Physics Co., Ltd from Sumitomo Chemical. This move is expected to strengthen GE HealthCare’s Pharmaceutical Diagnostics segment and enhance patient access to next-generation radiopharmaceuticals in Japan.

With Japan becoming a key player in the $7 billion global molecular imaging market, the addition of Nihon Medi-Physics is expected to expand GE HealthCare’s footprint in Japan. This acquisition is projected to be neutral to adjusted earnings per share in year one and accretive thereafter.

The global radiopharmaceuticals market is anticipated to reach $25.33 billion by 2031, with a CAGR of 6.5%. GE HealthCare’s latest acquisition aligns with industry growth trends, positioning the company for further success in the medical imaging sector.

Despite a recent 8.5% decline in share price, GE HealthCare’s acquisition and business prospects remain promising. The company’s strategic move to acquire Nihon Medi-Physics is expected to provide a significant boost to its operations and market position.

For investors seeking opportunities in the medical sector, GE HealthCare Technologies Inc., with its recent acquisition, presents a compelling investment choice. Other notable stocks in the industry include Cardinal Health, Cencora, and Boston Scientific Corporation, each showing strong growth potential and positive earnings track records.



Read more at Nasdaq: GEHC Stock Gains Following Buyout Completion to Boost Its PDx Arm